Renaissance Group’s OptimizeRx OPRX Stock Holding History

Renaissance Group’s Portfolio OPRX Stock Details OPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-32,085	Closed	-$879K	–	280
2022 Q2	$879K	Buy	32,085 +1,598	+5%	+$47.4K	0.05%	206
2022 Q1	$1.15M	Buy	30,487 +9,467	+45%	+$419K	0.05%	172
2021 Q4	$1.31M	Sell	21,020 -2,971	-12%	-$225K	0.05%	148
2021 Q3	$2.05M	Sell	23,991 -182	-0.8%	-$11.4K	0.09%	114
2021 Q2	$1.5M	Buy	+24,173	New	+$1.23M	0.06%	117

Other funds holding OPRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Avenir Corporation Alexandria, Virginia $821M AUM 4.23% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return

AIC

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

GIPM

G2 Investment Partners Management New York $549M AUM 179.59% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

Renaissance Group's OPRX Position: Q3 2022 in Review

Renaissance Group sold out of OptimizeRx (OPRX) in Q3 2022, closing a stake of 32,085 shares — an estimated $879K sold.

Renaissance Group first reported a position in OPRX in Q2 2021 and held it in 5 quarters. The position peaked at $2.05M in Q3 2021. 128 funds tracked by Wall St. Rank hold OPRX as of Q3 2022.

Renaissance Group reported no remaining OptimizeRx position as of Q3 2022 after selling out during the quarter.
Renaissance Group sold 32,085 OptimizeRx shares in Q3 2022, an estimated $879K.
Renaissance Group first reported a position in OptimizeRx in Q2 2021 and held it in 5 quarters.
Renaissance Group's OptimizeRx position peaked at $2.05M in Q3 2021.
128 funds tracked by Wall St. Rank held OptimizeRx as of Q3 2022.

Based on Renaissance Group's 13F filing for Q3 2022, filed 14 Nov 2022.